Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report

Table 1 Acute-phase reactants upon admission and during follow-up while receiving canakinumab treatment

	Reference ranges	On admission	After first administration of canakinumab	Last visit
CRP	0-0.1mg/dl	6.5mg/dl	1mg/dl	<0.33mg/dl
ESR	0-20mm/hr	100mm/hr	30mm/hr	10mm/hr
SAA	0-8mg/L	123mg/L	13.3mg/L	6.9mg/L

CRP C-reactive protein, ESR erythrocyte sedimentation rate, SAA Serum amyloid A

ISSN: 1752-1947